e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?

Autor: Mw Deininger, T Kegel, Susan Branford, Shadmehr Demehri, Giovanni Martinelli, Lc Lim, Peter Paschka, Thoralf Lange, T Koizumi, Beate Schultheis, Bj Druker, Andreas Hochhaus, Takeshi Sugimoto

Publikováno v: Leukemia. 19:681-684

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd84e11c6064d35348c3b45c1702008
https://doi.org/10.1038/sj.leu.2403604

Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins

Autor: Dwayne Barber, Jm, Mason, Fukazawa T, Ka, Reedquist, Bj, Druker, Band H, Andrea Ad, D.

Publikováno v: Europe PubMed Central

Transformation of hematopoietic cells by the Bcr-abl oncoprotein leads to constitutive tyrosine phosphorylation of a number of cellular polypeptides that function in normal growth factor-dependent cell proliferation. Recent studies have shown that th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d3f9e76835c5313c59efe25732a58943
https://pubmed.ncbi.nlm.nih.gov/9129019

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Autor: Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Blum WG; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Huang Y; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Welkie RL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Swords RT; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Traer E; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stein EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Lin TL; Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS., Archer KJ; Division of Biostatistics, The Ohio State University, Columbus, OH., Patel PA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Collins RH; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX., Baer MR; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Duong VH; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Arellano ML; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Stock W; Department of Medicine, The University of Chicago, Chicago, IL., Odenike O; Department of Medicine, The University of Chicago, Chicago, IL., Redner RL; Department of Medicine, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA., Kovacsovics T; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Deininger MW; Department of Internal Medicine, Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Zeidner JF; Division of Hematology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Olin RL; Department of Medicine, University of California, San Francisco, San Francisco, CA., Smith CC; Department of Medicine, University of California, San Francisco, San Francisco, CA., Foran JM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL., Schiller GJ; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA., Curran EK; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Koenig KL; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Chen T; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Martycz M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Stefanos M; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Marcus SG; Leukemia & Lymphoma Society, Rye Brook, NY., Rosenberg L; Leukemia & Lymphoma Society, Rye Brook, NY., Druker BJ; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Burd A; Leukemia & Lymphoma Society, Rye Brook, NY., Yocum AO; Leukemia & Lymphoma Society, Rye Brook, NY., Borate UM; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Mims AS; Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH., Byrd JC; Deparrtment of Internal Medicine, University of Cincinnati, Cincinnati, OH., Madanat YF; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

Publikováno v: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5297-5305.

Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.

Autor: Joshi SK; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA., Piehowski P; Pacific Northwest National Laboratory, Richland, Washington, USA., Liu T; Pacific Northwest National Laboratory, Richland, Washington, USA., Gosline SJC; Pacific Northwest National Laboratory, Richland, Washington, USA., McDermott JE; Pacific Northwest National Laboratory, Richland, Washington, USA.; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA., Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Tyner JW; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA., Agarwal A; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, USA., Tognon CE; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA., Rodland KD; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA; email: rodland@ohsu.edu.; Pacific Northwest National Laboratory, Richland, Washington, USA.

Publikováno v: Annual review of pharmacology and toxicology [Annu Rev Pharmacol Toxicol] 2024 Jan 23; Vol. 64, pp. 455-479. Date of Electronic Publication: 2023 Sep 22.

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.

Autor: Pino JC; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Posso C; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Joshi SK; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Nestor M; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Moon J; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Hansen JR; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Hutchinson-Bunch C; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Gritsenko MA; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Weitz KK; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Watanabe-Smith K; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, USA., Long N; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, USA., McDermott JE; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, USA., Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, USA., Liu T; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Tyner JW; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Agarwal A; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA; Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Piehowski PD; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA., Tognon CE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA., Rodland KD; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA. Electronic address: rodland@ohsu.edu., Gosline SJC; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA. Electronic address: sara.gosline@pnnl.gov.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Jan 16; Vol. 5 (1), pp. 101359.